Scleritis involves inflammation and swelling of the scleral and episcleral tissues, the fibrous white membrane that surrounds the eyeball excluding the cornea. Scleritis is classified as anterior or posterior and is subdivided further into diffuse, nodular and necrotizing scleritis with or without inflammation (scleromalacia perforans). Anterior scleritis is the most common form (80-85%) with the diffuse and nodular variants occurring almost equally, and it disproportionately impacts women between the ages of 40 and 60 who may have an underlying systemic inflammatory condition. Scleritis is associated with severe pain and it can lead to ocular complications including keratitis, uveitis, and glaucoma, and if left untreated it may cause vision loss.
About XOMA Corporation
XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier (Servier) through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes.More detailed information can be found at www.xoma.com . The XOMA Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960 Forward-Looking Statements Certain statements contained in this press release including, but not limited to, statements related to anticipated timing of initiation and successful completion XOMA's proof-of-concept program and clinical trials and the potential impact of allosteric modulation on the treatment of human diseases, or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.
CONTACT: XOMA Corporation Company and Investor Contact: Ashleigh Barreto 510-204-7482 email@example.com Juliane Snowden The Oratorium Group, LLC firstname.lastname@example.org Media Contact: Canale Communications Carolyn Hawley 619-849-5375 email@example.com